Elicera Therapeutics

The final payment amounts to approximately EUR 130,000, bringing the total amount received by the Company from the EIC Accelerator Fund to approximately EUR 2,380,000 to support the ongoing Phase I/IIa CARMA study with Elicera's CAR T-cell therapy ELC-301.

The CARMA study is a Phase I/IIa clinical trial evaluating the safety and preliminary efficacy of ELC-301 (a CD20-targeted CAR T-cell therapy armed with the iTANK platform) in patients with relapsed or refractory B-cell lymphoma. The grant from the EIC Accelerator Fund has been of great importance in financing the study in parallel with other funding sources.

This approval marks a successful conclusion of the formal reporting process to the European Commission/EIC and confirms that all reporting requirements have been fulfilled.

Relevance for Elicera

· The grant has strengthened the Company's financial position and enabled continued progress in the CARMA study, thereby delaying the need for additional capital.

· The approved final reporting strengthens Elicera's track record vis-à-vis both public funders and investors.

· The results from the CARMA study, which have shown promising clinical data so far, have been reported within the framework of the project.